CONDITION

Familial dysbetalipoproteinemia

An inherited condition that causes cholesterol-rich fat particles to build up in the blood

WHAT IT IS
Inherited buildup of cholesterol-rich remnant particles

BODY SYSTEM
Heart, circulation, and skin

MAIN SYMPTOMS
Often none, yellow skin deposits, leg pain, chest pain

WHAT CAUSES IT
Inherited APOE changes plus metabolic triggers

HOW IT IS DIAGNOSED
Lipid pattern, apolipoprotein B, and APOE genetic testing

MAIN TREATMENT
Heart-healthy habits and lipid-lowering medicines

CAN IT BE CURED?
No, inherited tendency remains lifelong

IS IT AN EMERGENCY?
Sometimes, with chest pain, stroke signs, or cold limb

LONG-TERM OUTLOOK
Usually manageable, but untreated artery risk can be serious

Overview

Familial dysbetalipoproteinemia is an inherited condition that affects how the body clears certain fat-carrying particles from the blood. These particles are called remnants because they remain after larger particles have delivered some of their fat to the body.

Remnants contain cholesterol and triglycerides. In this condition, they can build up and enter artery walls, causing atherosclerosis , or narrowing and hardening of the arteries.

The condition is most often linked to changes in the APOE gene. This gene provides instructions for apolipoprotein E, a protein that helps the liver recognize and remove remnant particles.

Having a related APOE pattern does not always cause active dysbetalipoproteinemia. Other health or hormonal factors often help bring out the abnormal lipid pattern, so the condition

may not become noticeable until adulthood.

Untreated remnant buildup can increase the risk of coronary artery disease and reduced blood flow to the legs. Treatment can often lower lipid levels substantially and reduce cardiovascular risk.

Symptoms

Many people have no symptoms from high lipid levels. The condition may first be found through a blood test or an assessment for artery problems.

Possible skin findings include xanthomas , which are usually painless cholesterol deposits beneath the skin. They can appear as:

Yellow-orange palm creases are particularly suggestive, but they do not confirm the condition. Other lipid disorders can also cause skin deposits.

Symptoms caused by narrowed arteries may include:

These symptoms have many possible causes and do not necessarily mean you have familial dysbetalipoproteinemia.

- Yellow or orange discoloration in the palm creases
- Raised yellow-red bumps over the elbows, knees, or buttocks
- Larger deposits around joints or tendons
- Chest pressure or discomfort during activity
- Shortness of breath with exertion
- Aching or cramping in the calves, thighs, or buttocks when walking
- Slow-healing foot wounds or a persistently cold foot

Causes and risk factors

Familial dysbetalipoproteinemia usually involves inherited APOE variants that make remnant particles harder for the liver to clear.

A common associated pattern is having two copies of the APOE2 form. However, most people with this pattern do not develop the full condition. Genetic results must therefore be interpreted alongside blood tests and medical history. Less common APOE variants may follow different inheritance patterns and cause high lipid levels across several generations.

Factors that may reveal or worsen the abnormal lipid pattern include:

These are called secondary causes because they are not the underlying inherited change. Treating them may improve lipid levels.

Smoking does not cause familial dysbetalipoproteinemia, but it greatly increases the cardiovascular risk associated with cholesterol-rich remnants.

- Excess body weight, especially around the waist
- Type 2 diabetes or insulin resistance
- An underactive thyroid
- Kidney or liver conditions
- Hormonal changes, including menopause
- Heavy alcohol use
- Some medicines that affect lipid metabolism

Diagnosis

Diagnosis requires more than a standard cholesterol result. A clinician will consider your lipid pattern, medical history, examination findings, and sometimes genetic testing.

A lipid panel measures total cholesterol, triglycerides, HDL cholesterol, and calculated or directly measured LDL cholesterol. Both cholesterol and triglycerides are often raised in familial dysbetalipoproteinemia. LDL cholesterol may not show the full burden because much of the harmful cholesterol is carried in remnants.

Other useful measurements include:

A high cholesterol burden with fewer apoB-containing particles than expected can suggest cholesterol-rich remnants.

APOE genetic testing can identify an associated genetic pattern, but a result alone does not prove active dysbetalipoproteinemia. Some people have the relevant pattern but normal lipid levels.

Specialist laboratories may separate lipoproteins when the diagnosis remains uncertain. Blood tests may also check thyroid function, blood glucose, liver function, and kidney function for factors that could worsen the lipid pattern.

Referral to a lipid specialist or genetics service may help when results are unclear, unusually severe, or found in several relatives.

- Non-HDL cholesterol , which includes cholesterol in all potentially artery-damaging particles
- Apolipoprotein B , or apoB, which estimates the number of these particles
- Ratios comparing cholesterol, triglycerides, and apoB

Treatment and management

Treatment aims to lower remnant cholesterol and reduce artery complications. The plan depends on lipid results, overall cardiovascular risk, existing artery disease, and other health needs.

Lifestyle measures may include eating more vegetables, whole grains, legumes, fish, nuts, and unsaturated fats while limiting saturated fat, refined carbohydrates, and heavily processed foods. Alcohol may need to be reduced or avoided when triglycerides are high.

Regular physical activity and gradual weight loss, when appropriate, can improve the body's handling of triglyceride-rich particles. Avoiding smoking is especially important. Contributing conditions, such as diabetes or an underactive thyroid, should also be treated.

Medicines are often needed. Options include:

A statin is commonly used when cardiovascular risk is raised, but treatment must be individualized. Combining lipid medicines requires clinical supervision because of possible side effects and interactions.

Monitoring often includes triglycerides, non-HDL cholesterol, and apoB rather than LDL cholesterol alone. Blood tests may also check for liver or muscle effects when relevant to the medicines used.

- Statins like atorvastatin or simvastatin , which reduce the liver's production of cholesterol-containing particles
- Fibrates , which can lower triglycerides and remnants
- Ezetimibe , which reduces cholesterol absorption from the intestine
- Other lipid-lowering treatments in selected situations

Complications

The main long-term complication is atherosclerosis caused by cholesterol-rich remnants collecting in artery walls.

This can lead to:

Leg artery problems may occur relatively early when the condition is untreated. Symptoms can progress from discomfort while walking to pain at rest or poorly healing wounds.

Xanthomas usually do not cause serious physical harm, but they may be uncomfortable or upsetting. They also show that cholesterol has accumulated in tissues.

Pancreatitis is not the defining complication, but it can occur if triglycerides become very high, particularly when another health factor is present.

- Coronary artery disease
- Heart attack
- Peripheral artery disease , reducing blood flow to the legs
- Stroke or other problems involving arteries to the brain

Prevention

The inherited APOE tendency cannot be prevented or removed. However, some factors that bring out or worsen the condition can be reduced.

Maintaining a healthy weight, staying active, limiting alcohol, not smoking, and managing diabetes or thyroid disease may lessen the lipid abnormality. These measures do not replace blood testing or medicine when treatment is needed.

Because APOE variants can run in families, close relatives may be offered lipid testing. Targeted genetic testing may be considered after discussion with a lipid or genetics specialist. Relatives carrying the same variant may have different lipid levels and cardiovascular risks.

Living with it and what to expect

Familial dysbetalipoproteinemia is lifelong, but its abnormal lipid pattern often responds well to treatment. Cholesterol and triglycerides may improve over weeks to months after contributing conditions are treated and lipid-lowering measures begin.

Skin deposits may flatten or fade as lipid levels fall, although this can take longer. Established artery narrowing may not disappear completely, so long-term treatment focuses on preventing plaque growth and cardiovascular events.

Regular follow-up usually includes blood tests, medicine reviews, and assessment of blood pressure, diabetes, smoking, and other cardiovascular risk factors. Treatment may need

adjustment if your weight, hormone status, kidney function, medicines, or health conditions change.

Most daily activities are not restricted. Exercise is usually encouraged within safe personal limits. If you have heart or circulation symptoms, discuss an appropriate activity plan before increasing exercise.

Consistent treatment can substantially improve the outlook, although it cannot guarantee that complications will never occur.

When to get medical help

Arrange a routine appointment if blood tests repeatedly show both high cholesterol and high triglycerides, particularly if LDL cholesterol does not explain the total cholesterol level. Yellow-orange palm creases, unexplained xanthomas, or a family history of unusual mixed lipid results also need assessment.

Seek prompt medical advice for new leg pain while walking, a slow-healing foot wound, or a foot that is repeatedly colder or paler than the other. These may indicate reduced circulation but are not always emergencies.

Call emergency services for:

These symptoms can indicate a heart attack, stroke, sudden loss of limb blood flow, or pancreatitis. Do not wait for a routine appointment.

- New chest pressure, squeezing, or pain, especially with sweating or nausea
- Sudden facial drooping, arm weakness, speech difficulty, or loss of balance
- A suddenly painful, pale, numb, or cold arm or leg
- Severe upper abdominal pain with persistent vomiting

Common questions

Is familial dysbetalipoproteinemia the same as familial hypercholesterolemia?

No. Familial hypercholesterolemia mainly causes high LDL particle levels. Familial dysbetalipoproteinemia causes cholesterol-rich remnant particles to accumulate, often raising both cholesterol and triglycerides.

Does an APOE2 result mean I have the condition?

Not by itself. Many people with two APOE2 copies never develop the characteristic lipid

pattern. Diagnosis also requires evidence of remnant buildup and assessment of contributing factors.

Can diet cure it?

No. Diet cannot remove the inherited tendency. Food choices, activity, weight management, and limiting alcohol can lower remnant levels, but many people also need medicine.

Why can my LDL cholesterol look normal when my total cholesterol is high?

Some cholesterol may be carried in remnant particles rather than LDL particles. Calculated LDL can also be less reliable when triglycerides are raised. Non-HDL cholesterol, apoB, and specialist tests can provide more information.

Will my children inherit it?

A child may inherit an APOE variant, but this does not always lead to active dysbetalipoproteinemia. The chance depends on the specific variant and the other APOE copy inherited. Genetic counselling can clarify risk within a family.

Will the yellow skin deposits go away?

Xanthomas may shrink or fade after lipid levels are controlled, but improvement can take months or longer. Persistent deposits can be reviewed if they cause discomfort or cosmetic concern.

Sources

- Hegele RA, Borén J, Ginsberg HN, and colleagues. "Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement." The Lancet Diabetes & Endocrinology . 2020;8(1):50-67.
- APOE-Related Familial Dysbetalipoproteinemia . GeneReviews, National Center for Biotechnology Information Bookshelf.
- Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) . Endotext, National Center for Biotechnology Information Bookshelf.
- Mach F, Baigent C, Catapano AL, and colleagues. "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk." European Heart Journal . 2020;41(1):111-188.
- Grundy SM, Stone NJ, Bailey AL, and colleagues. "2018 AHA/ACC Guideline on the Management of Blood Cholesterol." Circulation . 2019;139:e1082-e1143.